Biocept Files for $15M Public Offering | GenomeWeb

NEW YORK (GenomeWeb) – Biocept plans to offer about $15 million of its common stock in a public offering, the firm said in documents filed with the US Securities and Exchange Commission on Wednesday. 

The company has not priced its offering, but said that it plans to offer about 6.3 million shares of its stock. Its shares closed at $2.52 in Wednesday trade on the Nasdaq. 

Aegis Capital and Feltl and Co. are listed as the underwriters on the offering. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.